Related Experiment Video
Updated: Jul 12, 2025

The Soft Agar Colony Formation Assay
Published on: October 27, 2014
FTO-mediated LINC01134 stabilization to promote chemoresistance through miR-140-3p/WNT5A/WNT pathway in PDAC
Jin Lu1, Yongsheng Yang2, Xiangliang Liu1
1Cancer Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, China.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer most frequently detected at an advanced stage that limits treatment options to systemic chemotherapy, which has provided only marginal positive clinical outcomes. Currently, the first-line chemotherapeutic agent for PDAC is gemcitabine (GEM). However, the chemotherapy resistance to GEM is often overlooked in the clinical treatment of PDAC due to the lack of effective biological markers. Therefore, it is crucial to find new prognostic markers and therapeutic targets for patients with PDAC. In this study, we identified a novel regulatory mechanism in the development of resistance to GEM in PDAC. Here, we report that LINC01134 was significantly upregulated in primary tumors from PDAC patients. In vitro and in vivo functional studies revealed that LINC01134 promotes PDAC resistance to GEM through facilitating stem cell features and modulating the cell cycle. Mechanistically, LINC01134 interactes with tumor suppressor miR-497-5p in PDAC cells. Increased LINC01134 downregulates miR-140-3p to promotes the oncogenic WNT5A expression. Moreover, m6A demethylase FTO participated in the upregulation of LINC01134 by maintaining LINC01134 mRNA stability through YTHDF2. Taken together, the present study suggested FTO-mediated LINC01134 stabilization to promote chemotherapy resistance to GEM through miR-140-3p/WNT5A/WNT pathway in PDAC. Our study identified new prognostic markers and new therapeutic targets for patients with PDAC.
Insights
Pancreatic cancer (PDAC) resistance to gemcitabine (GEM) chemotherapy is a major challenge. This study reveals LINC01134 promotes GEM resistance by enhancing stemness and cell cycle modulation, offering new therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer often diagnosed at late stages, limiting treatment efficacy.
- Gemcitabine (GEM) is the first-line chemotherapy for PDAC, but resistance significantly hinders clinical outcomes.
- Lack of effective biomarkers for gemcitabine resistance necessitates the identification of novel prognostic markers and therapeutic targets.
Purpose of the Study:
- To elucidate a novel regulatory mechanism driving gemcitabine resistance in pancreatic ductal adenocarcinoma.
- To identify LINC01134 as a potential biomarker and therapeutic target for overcoming chemotherapy resistance in PDAC.
Main Methods:
- Analysis of LINC01134 expression in PDAC patient tumors.
- In vitro and in vivo functional studies to assess the role of LINC01134 in gemcitabine resistance.
- Investigation of the molecular mechanisms involving microRNAs (miR-497-5p, miR-140-3p), WNT5A, and FTO.
Main Results:
- LINC01134 was significantly upregulated in PDAC tumors.
- LINC01134 promotes PDAC gemcitabine resistance by enhancing stem cell features and modulating the cell cycle.
- LINC01134 downregulates miR-140-3p, leading to increased oncogenic WNT5A expression.
- FTO-mediated stabilization of LINC01134 contributes to gemcitabine resistance via the miR-140-3p/WNT5A/WNT pathway.
Conclusions:
- FTO-mediated stabilization of LINC01134 is a key mechanism promoting gemcitabine resistance in PDAC.
- LINC01134, regulated by FTO, represents a promising prognostic marker and therapeutic target for PDAC patients.
- Targeting the FTO-LINC01134-miR-140-3p-WNT5A axis could offer new strategies to overcome gemcitabine resistance in pancreatic cancer.
Related Concept Videos
Canonical Wnt Signaling Pathway
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Non-Canonical Wnt Signaling Pathways
lncRNA - Long Non-coding RNAs
Abnormal Proliferation

